Open access
Open access
Powered by Google Translator Translator

Pharmacology / Pharmaceutical Industry

Cohort study: Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S. 11 excess venous thromboembolic events per 100 000 vaccinations; 2.5 excess cerebral venous thrombosis per 100 000 vaccinations.

7 May, 2021 | 08:33h | UTC

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study – The BMJ

Editorial: Thromboembolism and the Oxford-AstraZeneca vaccine – The BMJ

Commentaries: Thrombosis and bleeding after the Oxford-AstraZeneca covid-19 vaccination – The BMJ Opinion AND Putting risks into context: covid-19 vaccines and blood clots – The BMJ Opinion AND Expert reaction to study from Denmark and Norway looking at rare blood clots after the Oxford-AstraZeneca vaccine – Science Media Centre

 

Commentary on Twitter

 


Opinion | Covid-19: Sputnik vaccine rockets, thanks to Lancet boost

7 May, 2021 | 08:31h | UTC

Covid-19: Sputnik vaccine rockets, thanks to Lancet boost – The BMJ

 

Commentary on Twitter

 


RCT: Therapeutic drug monitoring during infliximab induction does not improve disease remission in patients with chronic immune-mediated inflammatory diseases

7 May, 2021 | 08:27h | UTC

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (free for a limited period)

Commentary: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly

 

Commentary on Twitter

 


RCT: Among patients with rheumatoid arthritis in remission, tapering conventional DMARDs using half-dose resulted in disease flares in 25% of patients compared with 6% of patients in the stable-dose group.

7 May, 2021 | 08:26h | UTC

Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission: The ARCTIC REWIND Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases – JAMA (free for a limited period)

Commentary: Mixed Results with Refined Treatment Strategies for Rheumatic Diseases – Physician’s Weekly

 


Short review: How to diagnose and manage QT prolongation in cancer patients

7 May, 2021 | 08:18h | UTC

How to Diagnose and Manage QT Prolongation in Cancer Patients – JACC: CardioOncology

 

Commentary on Twitter (thread – click for more)

 


In shock move, US backs waiving patents on COVID vaccines. “The development from the Biden administration draws cheers from public health researchers and ire from drugmakers.”

6 May, 2021 | 09:10h | UTC

In shock move, US backs waiving patents on COVID vaccines – Nature

See also: U.S. will back proposal to waive intellectual property rights and boost Covid-19 vaccine production – STAT AND Statement from the Executive Director of UNAIDS, Winnie Byanyima on the decision by the United States of America to support the TRIPS waiver for COVID-19 vaccines – UNAIDS AND WHO Director-General commends United States decision to support temporary waiver on intellectual property rights for COVID-19 vaccines – World Health Organization

 

Commentary on Twitter

 


RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

6 May, 2021 | 09:08h | UTC

Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant – New England Journal of Medicine

 


Observational study in Qatar: Pfizer–BioNTech Covid vaccine is 89.5% effective against B.1.1.7 variant and 75.0% effective against B.1.351 variant. Vaccine effectiveness against severe, critical, or fatal disease with any SARS-CoV-2 variant was very high, at 97.4%.

6 May, 2021 | 09:06h | UTC

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants – New England Journal of Medicine

Commentary: Pfizer-BioNTech vaccine offers strong protection against key variants of concern, real-world data from Qatar shows – The Washington Post

 

Commentary on Twitter

 


Observational study in Israel: Pfizer-BioNTech is 95.3% effective against SARS-CoV-2 infection.

6 May, 2021 | 09:04h | UTC

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data – The Lancet

Commentaries: Expert reaction to Israel nation-wide study looking at Pfizer vaccine effectiveness – Science Media Centre AND Covid-19: Two doses of Pfizer vaccine are “highly effective” against infection, hospital admission, and death, study finds – The BMJ

 


Organ transplant recipients remain vulnerable to Covid-19 even after second vaccine dose.

6 May, 2021 | 09:03h | UTC

Organ Transplant Recipients Remain Vulnerable to Covid-19 Even After Second Vaccine Dose – Johns Hopkins Medicine

Original Study: Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients – JAMA

 


Cohort study shows inadequate antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients.

6 May, 2021 | 09:01h | UTC

Antibody response to mRNA SARS-CoV-2 vaccine among kidney transplant recipients – Prospective cohort study – Clinical Microbiology and Infection

 

Commentary on Twitter

 


[Press release – not published yet] Moderna announces positive initial booster data against SARS-CoV-2 variants of concern.

6 May, 2021 | 08:57h | UTC

Moderna Announces Positive Initial Booster Data Against SARS-CoV-2 Variants of Concern – Moderna

Commentary: We just got our first evidence that Moderna’s coronavirus booster shot works to fight variants – Insider

 

Commentaries on Twitter

 


Practice changing | A four-month rifapentine regiment with moxifloxacin is noninferior to the standard 6-month regimen in the treatment of tuberculosis.

6 May, 2021 | 08:56h | UTC

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis – New England Journal of Medicine

Commentary: Four-month TB treatment matches six-month standard of care – Aidsmap

 


RCT: Perioperative dexamethasone reduces postoperative nausea and vomiting and is not associated with increased risk of surgical-site infections, even among diabetic patients.

6 May, 2021 | 08:54h | UTC

Dexamethasone and Surgical-Site Infection – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Dexamethasone treatment safe in surgery – Monash University

 


RCT: The combination of liraglutide + exercise improves weight loss maintenance more than either treatment alone.

6 May, 2021 | 08:52h | UTC

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined – New England Journal of Medicine

Commentary: Liraglutide beneficial for post-diet weight loss maintenance – Medwire News

 


COVID has pushed medical research into remote trials, benefiting patients and scientists

5 May, 2021 | 08:38h | UTC

COVID Has Pushed Medical Research into Remote Trials, Benefiting Patients and Scientists – Scientific American

 


What’s the future of vaccines linked to rare clotting disorders? Science breaks down the latest

5 May, 2021 | 08:37h | UTC

What’s the future of vaccines linked to rare clotting disorders? Science breaks down the latest – Science

 


Covax: How will Covid vaccines be shared around the world?

5 May, 2021 | 08:35h | UTC

Covax: How will Covid vaccines be shared around the world? – BBC

Related: WHO chief – The world can bring the global COVID-19 pandemic under control in the coming months provided it distributes the necessary resources fairly AND A year in the COVID-19 vaccine scheme COVAX

 


China’s COVID vaccines are going global — but questions remain

5 May, 2021 | 08:32h | UTC

China’s COVID vaccines are going global — but questions remain – Nature

 


USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

5 May, 2021 | 08:30h | UTC

Draft Recommendation Statement: Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer – U.S. Preventive Services Task Force

Draft Evidence Review: Vitamin, Mineral, and Multivitamin Supplementation to Prevent Cardiovascular Disease and Cancer

 


ASCO Guideline Update: Appropriate systemic therapy dosing for obese adult patients with cancer

5 May, 2021 | 08:27h | UTC

Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update – Journal of Clinical Oncology

 


Prior SARS-CoV-2 infection boosts response to variants after first vaccine dose

4 May, 2021 | 08:51h | UTC

Prior SARS-CoV-2 infection boosts response to variants after first vaccine dose – Imperial College London

Original study: Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose – Science

 

Commentary on Twitter (thread – click for more)

 


WHO lists Moderna vaccine for emergency use

4 May, 2021 | 08:49h | UTC

WHO lists Moderna vaccine for emergency use – World Health Organization

 


WHO Inches Closer to Approval of Chinese Sinopharm and Sinovac Vaccines

4 May, 2021 | 08:49h | UTC

WHO Inches Closer to Approval of Chinese Sinopharm and Sinovac Vaccines – Health Policy Watch

 


Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

4 May, 2021 | 08:38h | UTC

2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation – EP Europace

Commentary: EHRA Updates Its Popular ‘Practical’ NOAC Guide – TCTMD

 


Stay Updated in Your Specialty

No spam, just news.